Oncology products

Anastrazol e Tab aromatase inhibitor Bicalutam ide Tab oral non stroidal antiandrogen orallyadministered chemotherape utic agent nucleoside analogue used as chemotherapy oral nonsteroidal aromatase inhibitor prostate cancer and hirsutism metastatic breast and colorectal cancer Pancreatic cancer, breast cancer, ovarian cancer, and lung cancer, and may be used for other cancers as well. hormonally-responsive breast cancer after surgery used alone or with other treatments, such as surgery or radiation, to treat early breast cancer in women Anastrozole binds reversibly to the aromatase enzyme through competitive inhibition, inhibits the conversion of androgens to estrogens in peripheral tissues (outside the CNS), and a few CNS sites in various regions within the brain. Binds to the androgen receptor (AR) and preventing the activation of the Receptor and subsequent upregulation of androgen responsive genes by androgenic hormones.In addition, bicalutamide accelerates the degradation of the androgen receptor. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue pro-drug and, once transported into the cell, must be phosphorylated by deoxycytidine kinase to an active form. Both gemcitabine diphosphate (dFdCTP) and gemcitabine triphosphate (dFdCTP) inhibit processes required for DNA synthesis. Letrozole prevents the aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome P450 unit

Capecitab ine Gemciyab ine

Tab

Lyophiliz ed injection

Letrozole

Tab